What were Sanofi's first-quarter 2026 sales and business operating income, and how did they compare to analyst expectations?

Sanofi reported first-quarter 2026 total sales of 10.51 billion euros ($12.29 billion), exceeding the Vara Research–compiled analyst consensus of 10.22 billion euros; quarterly business operating income was 2.97 billion euros ($3.47 billion), beating average analyst estimates of 2.85 billion euros.

How did Dupixent perform in Q1 2026, and what was its contribution to Sanofi's overall sales?

Dupixent sales rose 30.8% at constant exchange rates to 4.17 billion euros ($4.88 billion), surpassing analyst expectations of 3.89 billion euros, and accounted for nearly 40% of Sanofi’s total quarterly sales of 10.51 billion euros.

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Apr 22, 2026

Sanofi exceeded first-quarter earnings expectations with a 30.8% surge in Dupixent sales, while preparing for CEO Belén Garijo to take over in April after Paul Hudson's departure.

reuters

2026-04-22

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Sanofi's first quarter earnings edges past estimates ahead of CEO change

FAQ